EKF.L

EKF Diagnostics Holdings Plc
EKF Diagnostics Hldg - Investor Presentation – Revised start time
15th March 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9464G
EKF Diagnostics Holdings PLC
15 March 2024
 

 

EKF Diagnostics Holdings plc

("EKF", the "Company", or the "Group")

 

 Investor Presentation - Revised start time

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces a revised start time for its investor presentation taking place on Wednesday 20 March 2024.

 

Julian Baines, Executive Chair, and Stephen Young, Chief Financial Officer, will be hosting a live online presentation relating to the Company's full year results via the Investor Meet Company platform at the revised time of 3pm GMT on Wednesday 20 March 2024. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

 

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited to the event at the new start time.

 

If the new time is no longer convenient, please note that a recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair / Stephen Young, CFO

 Tel: +44 (0)29 2071 0570



Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Oliver Platts




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: +44 (0)7980 541 893 / +44 (0)7884 664 686  

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·   Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

 

·   Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASFEFWLELSEED]]>
TwitterFacebookLinkedIn